Bruton's Tyrosine Kinase as a Drug Discovery Target

被引:28
作者
Pan, Zhengying [1 ]
机构
[1] Celcra Genom, San Francisco, CA USA
关键词
D O I
10.1358/dnp.2008.21.7.1255308
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bruton's tyrosine kinase (Btk) is an important mediator in multiple signal transduction pathways. Fifteen years of research have revealed a complex role for Btk in hematopoietic cells. These studies suggest that Btk may be a promising target for therapeutic intervention for several complicated diseases. Inhibitors targeting the Btk kinase domain have been developed and show clear beneficial effects in animal models of rheumatoid arthritis, lymphoma and other diseases. Here, an overview of these studies is presented with an emphasis on results stemming from medicinal chemistry research. (C) 2008 Prous Science, S.A.U. or its licensors. All rights reserved.
引用
收藏
页码:357 / 362
页数:6
相关论文
共 51 条
[1]   Tec regulates platelet activation by GPVI in the absence of Btk [J].
Atkinson, BT ;
Ellmeier, W ;
Watson, SP .
BLOOD, 2003, 102 (10) :3592-3599
[2]   Bruton's tyrosine kinase links the B cell receptor to nuclear factor κB activation [J].
Bajpai, UD ;
Zhang, KM ;
Teutsch, M ;
Sen, R ;
Wortis, HH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (10) :1735-1744
[3]   Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model [J].
Cetkovic-Cvrlje, M ;
Uckun, FM .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (06) :821-827
[4]   Structural bioinformatics-based design of selective, irreversible kinase inhibitors [J].
Cohen, MS ;
Zhang, C ;
Shokat, KM ;
Taunton, J .
SCIENCE, 2005, 308 (5726) :1318-1321
[5]  
CURRIE KS, 2005, PRIVILEGED STRUCTURE
[6]  
Douhan J, 2007, ASSAY DRUG DEV TECHN, V5, P751, DOI [10.1089/adt.2007.093, 10.1089/adt.2007.9982]
[7]   Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells [J].
Feldhahn, N ;
Rio, P ;
Soh, BNB ;
Liedtke, S ;
Sprangers, M ;
Klein, F ;
Wernet, P ;
Jumaa, H ;
Hofmann, WK ;
Hanenberg, H ;
Rowley, JD ;
Müschen, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (37) :13266-13271
[8]   Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells [J].
Feldhahn, N ;
Klein, F ;
Mooster, JL ;
Hadweh, P ;
Sprangers, M ;
Wartenberg, M ;
Bekhite, MM ;
Hofmann, WK ;
Herzog, S ;
Jumaa, H ;
Rowley, JD ;
Müschen, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (11) :1837-1852
[9]   Cutting edge: Constitutive B cell receptor signaling is critical for basal growth of B lymphoma [J].
Gururajan, Murali ;
Jennings, C. Darrel ;
Bondada, Subbarao .
JOURNAL OF IMMUNOLOGY, 2006, 176 (10) :5715-5719
[10]   The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib [J].
Hantschel, Oliver ;
Rix, Uwe ;
Schmidt, Uwe ;
Buerckstuemmer, Tilmann ;
Kneidinger, Michael ;
Schuetze, Gregor ;
Colinge, Jacques ;
Bennett, Keiryn L. ;
Ellmeier, Wilf Ried ;
Valent, Peter ;
Superti-Furga, Giulio .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (33) :13283-13288